Pliant Therapeutics gets FDA Fast Track for PLN-101095 plus pembrolizumab
Pliant Therapeutics (PLRX) receives FDA Fast Track designation for PLN-101095 when used in combination with pembrolizumab to treat ICI-refractory solid tumors.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.